摘要
目的探讨中晚期前列腺癌患者单用促黄体生成素释放激素类药物与最大限度雄激素阻断疗法的疗效及安全性。方法回顾性分析2007年1月至2012年12月在南京医科大学第一附属医院及马鞍山市人民医院接受内分泌治疗的前列腺癌患者临床资料。分为单用促黄体生成素释放激素类药物组及最大限度雄激素阻断疗组,比较两组间疾病无进展生存期、总生存期及副反应。结果本研究共纳入患者资料392例,其中单药组120例,最大阻断组272例,平均年龄(67.6±6.6)岁,平均随访时间(33.1±8.3)月;两组间疾病无进展生存期(25.4 vs.25.3,P=0.354)及总生存期未见显著差异(34.6 vs.36.3,P=0.215)。单药组潮热(24.2%vs.34.9%,P=0.035)、贫血(8.3%vs.38.2%,P<0.001)、肝酶异常(5.8%vs.23.2%,P<0.001)、乏力(8.3%vs.18.8%,P=0.009)及便秘(3.3%vs.12.9%,P=0.004)的发生率显著低于最大阻断组。结论本研究比较了苏皖地区中晚期前列腺癌患者单用LHRH-a或MAB方案治疗的疗效及副作用,单用LHRH-a较MAB方案疗效相似,但部分副作用发生率较低,花费较少。
Objective To compare the efficacy and toxicity between luteinizing hormone releasing hormone analogue （LHRH-a） therapy and maximal androgen blockade （MAB） therapy in patients with advanced prostate cancer. Methods A series of 392 patients with advanced prostate cancer were included, 120 of whom received LHRH-a therapy （group A） and 272 received MAB therapy （group B）. Progression-free survival （PFS）, overall survival （US） and complication rates were com- pared between the two groups. Results There was no significant difference between the two groups in PFS （25.4% 1.0 vs. 25.3 ± 0.6, P = 0. 354） and OS （34.6 ±1.0 vs. 36.3 ± 0.6, P = 0.215）. Group A had significantly lower incidence rate of hot flash （24.2% vs. 34.9%,P=0.035）, anemia （8.3% vs. 38.2%, P〈0.001）, elevation of aminotransferase （5.8% vs. 23. 2%, P〈0.001）, fatigue （8.3% vs. 18.8%, P=0.009） and constipation （3.3% vs. 12.9%, P=0.004）. Conclusion LHRH-a therapy has similar efficacy as MAB but lower rate of side effects for patients with advanced prostate cancer.
出处
《现代泌尿外科杂志》
CAS
2015年第6期380-382,386,共4页
Journal of Modern Urology
基金
江苏省科技厅临床医学科技专项(No.BL2012027)
关键词
前列腺癌
内分泌治疗
疗效
副作用
雄激素阻断
prostate cancer
hormonal therapy
efficacy
side effect, androgen blockade
